Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
stenoparib
- Development stage
- Phase 2
- Lead developer
- Allarity Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Stenoparib is an **orally-available small molecule dual inhibitor** targeting **poly(ADP-ribose) polymerases 1 and 2 (PARP1/2)** and **tankyrase 1 and 2**, enzymes centrally involved in DNA repair and the Wnt/β-catenin signaling pathway[1][4][6][7]. By blocking both pathways, stenoparib interrupts cancer cell proliferation and DNA repair, offering a differentiated mechanism among PARP inhibitors and unique activity against tumors, particularly ovarian cancer including platinum-resistant and platinum-ineligible cases[1][4][5][6][7]. It is currently in Phase 2 trials for advanced ovarian cancer and previously demonstrated clinical benefit and favorable tolerability. Developed originally by Eisai Co. Ltd., stenoparib is now under exclusive rights for further development by Allarity Therapeutics[1][4][5][7]. Besides its antineoplastic action, stenoparib also demonstrates antiviral effects against SARS-CoV-2 and other coronaviruses *in vitro*[10].
- Brand names
- stenoparib
- Other names
- stenoparib
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)TNKS (Poly(ADP-ribose) Polymerase 5a)TNKS2 (Tankyrase 2)Pol II (RNA polymerase II elongation factors)
Beyond the preview
Go deeper on stenoparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on stenoparib.